Keywords: Eisai, Halaven, Breast cancer, South Korea, Approval

Eisai gets South Korean approval for breast cancer drug Halaven

Article | 04 September 2012

Print This

The South Korean sales subsidiary of Japanese drug major Eisai (TYO: 4523) has received approval from the regulatory authorities in South ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in